The GRIDD Phase 3 Delphi launched in December 2020 with Survey #1 and received input from 1154 adult dermatology patient respondents. They were located in 66 countries and represented over 91 disease conditions.
This is the largest number of respondents received in any previous GlobalSkin survey and the GRIDD co-lead researchers Dr./Prof. Matthias Augustin (Hamburg University) and Prof. Chris Bundy (Cardiff University) are very happy with these results. The GRIDD Team is very grateful to GlobalSkin Members whose recruitment efforts were instrumental in the success of the Delphi.
So, what’s next?
The researchers are analyzing the data from Survey #1 using a standard assessment rubric and will identify the questions and statements that either need editing, removing, or refining. They will then create Survey #2 as a shorter more concise version of Survey #1. Survey #2, expected to be launched in late April, will be shared with only those who completed Survey #1.
The success of the Delphi is reliant on dermatology patients to be the experts in determining what matters most when measuring patient impacts. We thank all patients for playing such an important role in this process.
Once the Delphi Survey #2 closes at the end of May the researchers will once again comb through the data and leverage the findings for Phase 4 and the design of PRIDD – Patient Report Impact of Dermatological Diseases – measurement tool (or measure). PRIDD will be an improved version of the Delphi Surveys and is expected to launch globally in late 2022 following extensive psychometric testing.